American Association for Cancer Research
ccr-23-1699_supplementary_figure_s3_suppfs3.pdf (604.74 kB)

Supplementary Figure S3 from GATA-3–dependent Gene Transcription is Impaired upon HDAC Inhibition

Download (604.74 kB)
journal contribution
posted on 2024-03-01, 11:00 authored by Xiangrong Geng, Chenguang Wang, Suhaib Abdelrahman, Thilini Perera, Badeia Saed, Ying S. Hu, Ashley Wolfe, John Reneau, Carlos Murga-Zamalloa, Ryan A. Wilcox

ChlP-seq occupancy binding peaks at GATA-3 target genes in vehicle/HDACi treated H9 cells


National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...



Many peripheral and cutaneous T-cell lymphoma (CTCL) subtypes are poorly responsive to conventional chemotherapeutic agents and associated with dismal outcomes. The zinc finger transcription factor GATA-3 and the transcriptional program it instigates are oncogenic and highly expressed in various T-cell neoplasms. Posttranslational acetylation regulates GATA-3 DNA binding and target gene expression. Given the widespread use of histone deacetylase inhibitors (HDACi) in relapsed/refractory CTCL, we sought to examine the extent to which these agents attenuate the transcriptional landscape in these lymphomas. Integrated GATA-3 chromatin immunoprecipitation sequencing and RNA sequencing analyses were performed in complementary cell line models and primary CTCL specimens treated with clinically available HDACi. We observed that exposure to clinically available HDACi led to significant transcriptional reprogramming and increased GATA-3 acetylation. HDACi-dependent GATA-3 acetylation significantly impaired both its ability to bind DNA and transcriptionally regulate its target genes, thus leading to significant transcriptional reprogramming in HDACi-treated CTCL. Beyond shedding new light on the mechanism of action associated with HDACi in CTCL, these findings have significant implications for their use, both as single agents and in combination with other novel agents, in GATA-3–driven lymphoproliferative neoplasms.

Usage metrics

    Clinical Cancer Research



    Ref. manager